药理上抑制MDM4可以缓解肺纤维化
Qianru Mei1, Zhenhua Yang1, Zhengkai Xiang2
1School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Theranostics
|June 7, 2023
概括
一种新药物,XI-011,通过向MDM4-p53通路,有效治疗肺纤维化. 这项研究显示出开发新型治疗异常性肺纤维化 (IPF) 的前景.
科学领域:
- 肺部病理学 肺部病理学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 异形性肺纤维化 (IPF) 是一种致命的无治肺病,需要对疾病机制和治疗点进行研究.
- 之前的研究发现,MDM4通过MDM4-p53通路促进肺纤维化,这表明该通路是潜在的治疗标.
研究的目的:
- 评估新型小分子抑制剂MDM4的XI-011在治疗肺纤维化的治疗疗效.
- 确定XI-011针对MDM4-p53通路是否可以解决已确定的肺纤维化.
主要方法:
- 用XI-011.11治疗人类原发性肌纤维细胞和肺纤维化的小鼠模型.
- 在XI-011治疗后评估MDM4表达和p53水平 (总和乙化).
- 在小鼠模型中评估纤维化分辨率和对正常肺纤维细胞和组织形态的影响.
主要成果:
- XI-011显著降低了MDM4表达,并在人类肌纤维细胞和小鼠纤维化模型中增加了总和乙化p53水平.
- 在小鼠中,XI-011治疗导致肺纤维化的解决.
- 没有观察到对正常纤维细胞活力或健康肺组织形态的显著影响.
结论:
- 在临床前的模型中,XI-011在解决肺纤维化方面表现出有效性.
- 使用XI-011准MDM4-p53通路,代表了针对异常性肺纤维化的有前途的治疗策略.
- XI-011可能是治疗肺纤维化的潜在候选药物.
相关概念视频
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
199
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
199